News Room

  • Co-Diagnostics, Inc. to Undergo ISO 13485:2016 Audit

    Co-Diagnostics, Inc. to Undergo ISO 13485:2016 Audit Audit to prepare for eventual sales into the US market August 10, 2017 07:30 AM Eastern Daylight Time SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, will be undergoing a Stage […]
  • Co-Diagnostics, Inc. to Attend AACC 2017

    Co-Diagnostics, Inc. to Attend AACC 2017 August 02, 2017 12:12 PM Eastern Daylight Time SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, will be sending Company representatives on August 2-3, 2017, to attend the 69th AACC Annual Scientific Meeting […]
  • Co-Diagnostics, Inc. Verifies Zika CoPrimer™ Test

    Co-Diagnostics, Inc. Verifies Zika CoPrimer™ Test   SALT LAKE CITY, July 27, 2017 (GLOBE NEWSWIRE) — Co-Diagnostics, Inc. (NASDAQ:CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company that has a unique, proprietary platform for the development of diagnostic tests, has completed principle design and verification of its Zika test built on the Company’s CoPrimer™ technology. The […]
  • Co-Diagnostics, Inc. Announces Joint Venture in India

    Co-Diagnostics, Inc. Announces Joint Venture in India   SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company that has a unique, proprietary platform for the development of diagnostic tests, officially announced today the recent incorporation of CoSara Diagnostics, Pvt., Ltd., a Joint Venture for manufacturing with Synbiotics Limited. Synbiotics is […]
  • Co-Diagnostics, Inc. to Use IPO Proceeds to Expand Operations

    Co-Diagnostics, Inc. to Use IPO Proceeds to Expand Operations SALT LAKE CITY, UTAH (PRWEB) JULY 17, 2017 Salt Lake City, UT – July 17, 2017 – Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company that has developed and intends both to manufacture and sell reagents used for diagnostic tests, has completed its […]
  • Co-Diagnostics, Inc. Announces Pricing of IPO

    Co-Diagnostics, Inc. Announces Pricing of IPO Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company that has developed and intends to manufacture and sell reagents used for diagnostic tests, announced today that its initial public offering of 1,178,532 shares of common stock has been priced at $6.00 per share. Total gross proceeds […]
  • Eureka Labs hosts Co-Diagnostics and touts partnership

    Following a visit to Eureka Medical Laboratories (EML) in Georgetown, Guyana, EML was featured in an article in the Guyana Times. In speaking of the event, Co-Diagnostics president and CEO Dwight Egan said: “We plan to make available a large menu of tests over the coming year that will enable the citizens of Guyana to […]
  • Co-Diagnostics mention in local press

    Co-Diagnostics received a mention from a local news outlet for being on the front lines of the war on Zika. The full text can be found by clicking the headline here: ‘It’s a full-frontal attack’: Utah companies, universities continue Zika research    
  • Co-Diagnostics Presents Technology to Woodlands Hospital, Guyana

    Co-Diagnostics CEO Dwight Egan is currently visiting the countries of Guyana and Trinidad and Tobago, where he has been invited to introduce our revolutionary testing solutions to select hospitals and laboratories in those regions. On October 24, 2016, Mr. Egan and two members of our science team presented Co-Diagnostics’ Zika Virus Rapid Test™  to staff and press […]
  • Patent Approved for HotStart Technology

    We are happy to announce that earlier this month the company received notification that our patent titled “Nucleic Acid Hotstart Technology” has been approved by the US Patent office. Once the patent has been officially granted, we will issue a press release containing the US Patent Number. The patent abstract reads: “The present invitation relates […]
  • Fox 13 broadcast: Utah based company developing a test to detect Zika Virus

    As news of our work on Zika virus continues to generate interest, another story was recorded and aired yesterday. This coverage can be found here.
  • Spread of Zika virus prompting Utah researchers to find treatment

    Following our recent press release, the local NBC affiliate station spent some time in our lab to discuss the efforts of our team of experts to develop a diagnostic for Zika virus. The story can be found here.
  • Co-Diagnostics Prepares Zika Virus Diagnostics Proposal

    See original release on PRWeb. SANDY, UT (PRWEB) FEBRUARY 04, 2016 Co-Diagnostics, Inc. announced today that the company has begun the preliminary test design process to develop a diagnostic for the mosquito-borne Zika virus and has prepared proposals to be submitted to the governments of affected Latin American countries. Zika virus is rarely fatal, but […]
  • Expanded ISO certification received

    On January 14th, the company received official certificates for ISO 13485 : 2003 and ISO 9001 : 2008, with an expanded scope from the previous certification announced in 2015. The registration numbers, no. 10013216 MP23 and no. 10013216 QM08 respectively, remain unchanged from the previous certifications. Whereas the previous certifications were granted to DNA Logix […]
  • 2015 SALSS Presentation

    View Release on PRWeb Co-Diagnostics CEO to present at 2015 SALSS in Stockholm, Sweden SANDY, UT (PRWEB) AUGUST 20, 2015 Co-Diagnostics CEO Dwight Egan will be a presenter at the 2015 Swedish-American Life Science Summit, taking place in August 19-21 in Stockholm, Sweden, the company confirmed today. The SALSS began 11 years ago as a […]